All News

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and user-friendly diagnostic methods are key.

This research investigated averted hospitalizations in Oregon and Washington, which had greater than 75% uptake of at least 1 dose of an mRNA-based COVID vaccine.

Medication-assisted treatment is an excellent approach to managing addiction and related emotional symptoms, Rachel Rohaidy, MD, of Miami Neuroscience Institute with Baptist Health, explains.

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but requires methods of improving adherence to follow-up.

The Kidney Disease: Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney disease (CKD) management.

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.

Steven Daniel Daveluy, MD, FAAD, advocates for dermatologists to adopt cultural humility, engage in continuous education, and navigate ethical considerations to provide equitable and supportive care to LGBTQ patients.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving quality of life in patients with moderate to severe scalp psoriasis.

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.

This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.

Experts stressed the importance of dermatologists engaging in climate advocacy and adopting sustainable practices, as their actions may inspire others to follow suit.

Shawn Kwatra, MD, FAAD, physician scientist at the University of Maryland Medical System, presented data at the American Academy of Dermatology 2025 annual conference on the rapid efficacy of topical ruxolitinib for itch and inflammation, while also outlining a comprehensive approach to chronic pruritus management.

Despite a surge in telemental health use after the onset of the COVID-19 pandemic, minority racial/ethnic group children had lower utilization rates than White children, according to Xin Hu, PhD, MSPH.

Elizabeth Jones, MD, FAAD, Thomas Jefferson University Hospitals, advocates for teledermatology as a vital tool to enhance health care equity by improving access for underserved populations and reducing physician burnout.

Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.

Myasthenia gravis is a neuromuscular junction disorder with a hallmark of progressive muscle weakness and frequent manifestation of otolaryngologic dysfunction, such as difficulty swallowing and speech disorder.

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198), emphasizing the balance between treatment efficacy and safety.

A dietary fiber intake between 14.4 and 26.7 g reduced the risk of osteoarthritis, but an intake above this dose was not significantly protective.

Experts shared details on health care contracting, setting up a centralized prior authorization pilot, and use of advocacy to win pharmacy benefit manager reforms at the state level.

Lawrence Eichenfield, MD, FAAD, from Rady Children's Hospital and UC San Diego School of Medicine, highlighted the importance of shared decision-making in atopic dermatitis treatment, emphasizing personalized care based on patient history and the favorable long-term safety profile of topical ruxolitinib.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).

Amid limited access to pediatric dermatologists nationwide, pediatric patients of color with atopic dermatitis (AD) are particularly affected by social determinants of health, further impacting their outcomes.

Rebecca Vasquez, MD, FAAD, University of Texas Southwestern Medical Center, emphasizes the necessity of addressing social determinants to improve dermatological care and access for underserved populations.

Martina Cartwright, PhD, RD, and Lawrence J. Green, MD, FAAD, both recommend the Mediterranean diet to reduce inflammation and manage some dermatological symptoms.

States must analyze the data on Medicaid and social determinant programs to understand the consequences of how potential policy changes will impact residents, Molly Dean, MSW, Siftwell, explains.

Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen receptor (CAR) T-cell therapy, specifically allogeneic, which uses healthy donor cells.

Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.

Revakinagene taroretcel-lwey (Encelto; Neurotech), an allogeneic encapsulated cell-based gene therapy, is the first therapy to be approved for macular telangiectasia type 2.